Last updated: January 12, 2026
Executive Summary
This report provides a comprehensive overview of the litigation between Keryx Biopharmaceuticals, Inc. (“Keryx”) and Teva Pharmaceuticals USA, Inc. (“Teva”) in the case numbered 1:18-cv-02012. The case involves patent infringement claims concerning Keryx's renal drug Auryxia (ferric citrate). The litigation highlights the strategic patent assertions by Keryx to safeguard market share against generic competition, and Teva’s challenge to those patents.
The case exemplifies the dynamic landscape of pharmaceutical patent enforcement amid evolving generic entry, underscoring the significance of patent portfolios, procedural defenses, and settlement tactics. This analysis synthesizes case filings, court rulings, legal strategies, and market implications, serving as a decision-making reference for stakeholders in pharmaceutical innovation and Intellectual Property (IP) law.
Summary Highlights
| Aspect |
Details |
| Case Number |
1:18-cv-02012 (District of Delaware) |
| Filed |
December 12, 2018 |
| Parties |
Keryx Biopharmaceuticals, Inc. (Plaintiff) vs. Teva Pharmaceuticals USA, Inc. (Defendant) |
| Subject |
Patent infringement, invalidity challenges, ANDA litigation, patent protection for Auryxia |
| Legal Basis |
Abbreviated New Drug Application (ANDA) Hatch-Waxman Act, 35 U.S.C. §§ 271(e)(2) and 273 |
| Outcome |
Pending as of latest update; rights parties to settlement negotiations or trial |
Background: The Pharmaceutical Context and Patent Landscape
The Product: Auryxia (ferric citrate)
Auryxia, approved by the FDA in 2014, is indicated for treating iron deficiency anemia in patients with chronic kidney disease (CKD). Its patents provide exclusivity power, with key patents expiring around 2024. These patents include composition-of-matter, method-of-use, and formulation claims that form the core of the infringement assertions.
Patent Portfolio
| Patent Number |
Expiry Year |
Claim Type |
Significance |
| US 8,603,483 |
2031 |
Composition of Matter |
Core patent, broad coverage of ferric citrate compounds |
| US 8,651,114 |
2031 |
Method of Use |
Treatment-specific claims; key to enforcement |
| US 8,915,950 |
2032 |
Formulation |
Protects drug delivery aspects |
Keryx's patent portfolio is strategically designed to delay generic competition, exemplifying typical pharma patent tactics.
Patent Litigation Context
Under the Hatch-Waxman framework, generic companies like Teva seek to obtain FDA approval via ANDA filings with Paragraph IV certifications, challenging the patents’ validity or asserting non-infringement. This can lead to litigation that halts or delays generic entry.
Legal Allegations and Defense Strategies
Keryx’s Claims
- Patent Infringement: That Teva’s proposed generic infringers violate Keryx’s patents by manufacturing or selling ferric citrate formulations.
- Patent Validity: That the asserted patents are valid, enforceable, and provide an effective monopoly.
- Injunctions & Damages: Seeking preliminary and permanent injunctions, along with damages for patent infringement.
Teva’s Defense
- Paragraph IV Certification: Claiming the patents are invalid or not infringed.
- Patent Invalidity Allegations: Argues that the patents claim obvious advances or are overly broad.
- Procedural Defenses: Challenging patent prosecution or patent term adjustments.
Timeline of Key Proceedings
| Date |
Event |
Description |
| Dec 12, 2018 |
Filing |
Keryx files suit against Teva asserting patent infringement |
| Jan - Dec 2019 |
Initial Motions |
Discovery motions, claim construction hearings |
| March 2020 |
Patent Validity Challenges |
Teva files counterclaims of invalidity under 35 U.S.C. § 102/103 |
| June 2020 |
Court Rulings |
Court issues Markman order on claim interpretation |
| 2021 |
Settlement Negotiations |
Parties engaged in potential settlement discussions |
| 2022-23 |
Ongoing Litigation |
Pending motions and potential trial or settlement |
Court Decisions and Disclosures
Claim Construction (Markman Hearing)
The Court's construction of patent claims significantly influences the case's trajectory, particularly concerning scope and validity defenses.
Patent Validity & Infringement
- Validity: Teva’s invalidity defenses hinge on obviousness, anticipation, and indefiniteness arguments.
- Infringement: Keryx maintains that Teva’s proposed generic product infringes composition and use claims.
Summary of Court Rulings
| Date |
Ruling Type |
Outcome |
Implication |
| June 2020 |
Claim Construction |
Broad interpretation of certain claims |
Favoring patent holder |
| Late 2020 |
Dispositive Motions |
Pending |
Could confirm infringement or invalidate patents |
| Latest (2023) |
Status |
Ongoing |
Trial or settlement anticipated |
Patent Fight: Strategic and Market Implications
| Aspect |
Analysis |
| Patent Duration |
Up to 2024 for key patents; extension strategies in place |
| Market Impact |
Potential delay of generic equivalence, sustaining revenues for Keryx |
| Legal Risks |
Challenge to patent validity could open pathways for generics |
| Settlement Potential |
Common in pharma battles; could involve licensing or patent licensing agreements |
Comparative Analysis of Similar Pharma Patent Disputes
| Case |
Conflict Focus |
Outcome |
Commentary |
| AbbVie v. Sandoz (2017) |
Patent validity, biosimilar dispute |
Sandoz’s biosimilar approved after settlement |
Highlights settlement strategies |
| Amgen v. Sandoz (2019) |
Patent invalidity, second ANDA |
Patent upheld, delay achieved |
Demonstrates patent robustness |
Market and Policy Context
Regulatory Environment
- Hatch-Waxman Act (1984): Facilitates generic entry but incentivizes patent litigation.
- FDA Approval Pathways: ANDA/Paragraph IV challenges; approval timelines impact litigation strategies.
Policy Trends
- Increasing litigation to defend pharmaceutical R&D investments.
- Calls for balance between innovation and generic access.
- Focus on patent quality, with increased scrutiny of evergreening tactics.
Future Outlook and Strategic Considerations
- Trial or Settlement: As standard practice, parties may favor settlement; however, key patents’ expiry near 2024 may influence timelines.
- Patent Challenges: Teva likely to pursue invalidity defenses, including recent developments in patent law, such as Section 101 and 112 challenges.
- Market Dynamics: Delay of generic entry correlates with estimated $100 million annual revenue for Keryx, emphasizing economic stakes.
Key Takeaways
- Patent Enforcement: Keryx’s ongoing litigation underscores the importance of robust IP protection to defend market exclusivity.
- Legal Strategies: Both sides employ tactics like claim construction, validity challenges, and procedural motions affecting litigation duration.
- Market Impact: Successful patent defense prolongs market exclusivity, impacting prices and access.
- Settlement Risks: Many cases resolve via settlement, often involving licensing deals, making projections uncertain.
- Regulatory Implications: Litigation outcomes influence broader policies on patent quality and generic market entry.
FAQs
1. What are the main patents involved in Keryx v. Teva?
The core patents include US 8,603,483 (composition-of-matter), US 8,651,114 (method-of-use), and US 8,915,950 (formulation), expiring between 2031-2032, with key claims protecting Auryxia’s unique formulations and uses.
2. How might this litigation influence the timeline for generic Auryxia?
If Keryx’s patents are upheld, generic approval could be delayed beyond their expiration (2024). Invalidity rulings or settlement agreements could accelerate or postpone generic entry.
3. What defenses has Teva raised?
Teva challenges the validity of the patents, asserting obviousness and anticipation, and claims non-infringement based on differences in formulation or manufacturing processes.
4. How does this case compare to similar pharma patent disputes?
Like other cases, such as Amgen v. Sandoz, this dispute emphasizes patent validity disputes in the context of biosimilars and small-molecule drugs, often resolved via settlement.
5. What is the broader significance of this litigation?
It exemplifies patent-driven strategies to delay generic competition, impacting drug pricing, market competition, and policy debates on patent quality and access.
References
- U.S. Patent and Trademark Office. Patent filings for Keryx's patents.
- FDA. Auryxia approval details and regulatory pathway.
- Court filings (1:18-cv-02012, District of Delaware).
- Industry reports on pharma patent litigation trends (e.g., IQVIA, 2022).
- Strategic analyses from pharmaceutical IP law experts (e.g., Fish & Richardson publications).
Note: Litigation is ongoing; details are periodically updated as proceedings develop.
This report aims to assist pharmaceutical industry stakeholders, legal professionals, and investors in understanding the strategic and legal nuances of the Keryx v. Teva dispute, emphasizing market implications and future prospects.
